NCT06211751View on ClinicalTrials.gov

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Hematologic Malignancy
Interventions
DRUG

TQB3909 tablets

TQB3909 is a protein inhibitor.

DRUG

TQB3702 tablets

TQB3702 is a kinase inhibitor.

Trial Locations (1)

450008

Henan Cancer Hospital, Zhengzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY